LiDCO Group plc (AIM: LID), the UK-based cardiovascular monitoring company, is pleased to announce approval by the Swiss regulatory body Swissmedic for the LiDCO System lithium chloride injection. Lithium chloride is used in conjunction with the LiDCOplus Monitor to provide an absolute measure of a patient’s cardiac output. This latest registration now provides LiDCO with full marketing approval to sell into 14 European countries.

Terry O’Brien, Chief Executive of LiDCO, stated: “Switzerland is Europe’s highest per capita income country, has one of the best health care systems in the world and spends 11% of the gross national product on health care. We expect that our distribution partner Homedica will establish Switzerland as an important market for LiDCO’s products.”

About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London where the Company maintains a research base.

The Company's manufacturing facility is in Hoxton, London and its current products are:

• LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;
• LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.

Distribution Network:

The Company has now achieved registration of its products in 17 markets in Europe, the USA, Brazil and Japan. It sells direct to the NHS in the UK, and through a worldwide network of specialty critical care distributors.